<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Zai-Lab-Ltd-Unsponsored-ADR-US98887Q1040">Zai Lab Ltd. Unsponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260806560438/en/Zai-Lab-Announces-Second-Quarter-2026-Financial-Results-and-Recent-Corporate-Updates/">Zai Lab veröffentlicht Finanzergebnisse für das zweite Quartal 2026 und aktuelle Unternehmensupdates</a>
    </div>

      <div class="me-0 me-md-5">
        SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) gab heute die Finanzergebnisse für das zweite Quartal 2026 sowie aktuelle Produkt-Highlights und Unternehmensupdates bekannt. „Zai Lab tritt in ein spannendes neues Kapitel unserer Entwicklung ein“, sagte Dr. Samantha Du, Gründerin, Vorsitzende und Chief Executive Officer von Zai Lab. „In den vergangenen Ja...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Zai-Lab-Ltd-Unsponsored-ADR-US98887Q1040">Zai Lab Ltd. Unsponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260803575802/en/U.S.-FDA-Grants-Orphan-Drug-Designation-to-Zai-Lab%E2%80%99s-DLL3-Targeting-ADC-Zocilurtatug-Pelitecan-Zoci-for-the-Treatment-of-Neuroendocrine-Carcinomas-NECs/">US-FDA gewährt Orphan-Drug-Status für Zai Labs DLL3-gerichteten ADC Zocilurtatug Pelitecan (Zoci) zur Behandlung von neuroendokrinen Karzinomen (NECs)</a>
    </div>

      <div class="me-0 me-md-5">
        SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) gab heute bekannt, dass die U.S. Food and Drug Administration (FDA) Zocilurtatug Pelitecan (zoci, ehemals ZL-1310), dem potenziellen First-in-Class Delta-like ligand 3 (DLL3) Antikörper-Wirkstoff-Konjugat (ADC) des Unternehmens, den Orphan-Drug-Status (ODD) für die Behandlung von neuroendokrinen Karzinomen ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Zai-Lab-Ltd-Unsponsored-ADR-US98887Q1040">Zai Lab Ltd. Unsponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260616338405/en/Zai-Lab-Receives-EMA-Orphan-Drug-Designation-for-Zocilurtatug-Pelitecan-Zoci-in-Pulmonary-Neuroendocrine-Carcinomas/">Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas</a>
    </div>

      <div class="me-0 me-md-5">
        SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company&#39;s potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for the treatment of pulmonary neuroendocrine carcinoma...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Zai-Lab-Ltd-Unsponsored-ADR-US98887Q1040">Zai Lab Ltd. Unsponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260608963481/en/Zai-Lab-Receives-China-NMPA-Approval-of-TIVDAK%C2%AE-tisotumab-vedotin-for-injection-for-the-Treatment-of-Adult-Patients-with-Recurrent-or-Metastatic-Cervical-Cancer/">Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer</a>
    </div>

      <div class="me-0 me-md-5">
        SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China&#39;s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Zai-Lab-Ltd-Unsponsored-ADR-US98887Q1040">Zai Lab Ltd. Unsponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260521314535/en/Zai-Lab-Announces-Changes-to-Senior-Leadership-Team/">Zai Lab Announces Changes to Senior Leadership Team</a>
    </div>

      <div class="me-0 me-md-5">
        SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22. &quot;I want to thank Josh for his cont...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Zai-Lab-Ltd-Unsponsored-ADR-US98887Q1040">Zai Lab Ltd. Unsponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260511041273/en/Zai-Lab-Receives-U.S.-FDA-Fast-Track-Designation-for-Zocilurtatug-Pelitecan-Zoci-a-DLL3-Targeting-ADC-for-Treatment-of-Extrapulmonary-Neuroendocrine-Carcinomas-epNECs/">Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)</a>
    </div>

      <div class="me-0 me-md-5">
        SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company&#39;s potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for the treatment of extrapulmonary neuroendocrine car...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negativ
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Zai-Lab-Ltd-Unsponsored-ADR-US98887Q1040">Zai Lab Ltd. Unsponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">MarketBeat</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.marketbeat.com/instant-alerts/zai-lab-q1-earnings-call-highlights-2026-05-09/?utm_source=snapi">Zai Lab Q1 Earnings Call Highlights</a>
    </div>

      <div class="me-0 me-md-5">
        Zai Lab NASDAQ: ZLAB reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management emphasized progress across its global oncology and immunology pipeline and pointed to multiple upcoming regulatory and clinical milestones.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Zai-Lab-Ltd-Unsponsored-ADR-US98887Q1040">Zai Lab Ltd. Unsponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260507022619/en/Zai-Lab-Announces-First-Quarter-2026-Financial-Results-and-Recent-Corporate-Updates/">Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates</a>
    </div>

      <div class="me-0 me-md-5">
        SHANGHAI &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2026, along with recent product highlights and corporate updates. “We continue to accelerate the development of our global pipeline, with numerous clinical trials underway across oncology and immunology,” said Dr. Samantha Du, Founder, Chairperson a...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Zai-Lab-Ltd-Unsponsored-ADR-US98887Q1040/load_more?page=3">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>